Fiche du document
- doi: 10.1002/ccr3.1032
- issn: 2050-0904
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/ccr3.1032
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/28781850
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/2050-0904
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F5940E9F0C9D2
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Mots-clés
Acute lymphoblastic leukemia; T315I BCR‐ABL; treatment maintenance; tyrosine kinase inhibitorSujets proches
Upkeep Preventive maintenanceCiter ce document
J. Noetzli et al., « T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance. », Serveur académique Lausannois, ID : 10.1002/ccr3.1032
Métriques
Partage / Export
Résumé
We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.